ABMD News and Press, ABIOMED Inc. From 11/06/22

NEW YORK, NY / ACCESSWIRE / November 6, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Altra Industrial Motion Corp. (NA...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . For further details see: Wall Street Breakfast: What Moved Markets

It's not surprising that Johnson & Johnson (NYSE: JNJ) has a deal in the works to buy Abiomed (NASDAQ: ABMD) , the maker of the Impella heart pump. The only surprising thing is that it took this long for it to happen. More than 11 years ago, then-Johnson & Johnso...

Summary JNJ announced the $16.6 billion-plus acquisition of Abiomed, agreeing to pay $380/share in cash upfront and up to $35/share tied to longer-term performance targets. Abiomed sells heart pumps that assist damaged hearts with their core pumping functions, improving survival a...

Summary Johnson & Johnson is betting that devices designed to keep patients’ hearts pumping will do something similar to its revenue growth. The U.S. healthcare firm is paying $16.6 billion to buy cardiac-device maker Abiomed, a transaction that will create a measly ret...

Stocks edged lower for the second day in a row on Tuesday, as investors positioned themselves ahead of the Federal Reserve's interest rate decision, due out during Wednesday's trading. The market is widely expecting another rate hike of 75 basis points. While macro concerns set the over...

Shares of Abiomed (NASDAQ: ABMD) soared 50% on Tuesday after the medical device maker struck an acquisition deal with Johnson & Johnson (NYSE: JNJ) . J&J will make a tender offer for Abiomed's publicly traded shares. Under the terms of the agreement, Abiomed's sh...

Abiomed, Inc. (ABMD) Q2 2023 Earnings Conference Call November 01, 2022, 08:00 AM ET Company Participants Jessica Moore - Vice President of Investor Relations, Johnson & Johnson. Joaquin Duato - Chief Executive Officer, Johnson & Johnson Michael Joaquin -...

Abiomed ( NASDAQ: ABMD ) is unlikely to see a higher bid that Johnson & Johnson's ( NYSE: JNJ ) $16.6 billion deal, according to BTIG. The 50% premium offered and limited number of companies that could potentially do a deal of the size makes another bid unlik...

ABIOMED Inc ( NASDAQ: ABMD ) opened about 50% up on Tuesday after Johnson & Johnson ( NYSE: JNJ ) said it will buy the heart pump maker for $16.6 billion. ABIOMED stock shot up in line with the proposed premium J&J is willing to pay $380 a share for the medical d...